Posted by bodhisattva_guy on February 5, 2011, at 0:19:58
In reply to Re: Viibryd Approved; works on Serotonin and Dopamine, posted by bodhisattva_guy on February 4, 2011, at 23:59:37
Well, it's quite complex, so I will add additional info from the article mentioned above:
"However, the effects for pindolol have not been observed with vilazodone. In the same PET clinical trial, vilazodone
exhibited twice the receptor occupancy in the midbrain raphe nucleus, a small beaded structure with high concentrations of presynaptic 5-HT1A
autoreceptors, compared with occupancy in cortical areas [688282]. Consistent with the action of a selective 5-HT1A receptor
agonist, such as 8-OH-DPAT, marked increases in dopamine and norepinephrine neurotransmission would be expected [742319]. However, this effect on dopamine or norepinephrine was not produced by vilazodone"Another, older article,
"Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone
by
Hughes ZA, Starr KR, Langmead CJ, Hill M,
Bartoszyk GD, Hagan JJ, Middlemiss DN, Dawson LA.
Neuropharmacology Research,
Psychiatry CEDD, Glaxo Smith Kline,
New Frontiers Science Park,
Third Avenue, Harlow, Essex, CM19 5AW, UK.
Eur J Pharmacol. 2005 Mar 7;510(1-2):49-57.ABSTRACT
Vilazodone has been reported to be an inhibitor of 5-hydoxytryptamine (5-HT) reuptake and a partial agonist at 5-HT1A receptors. Using [35S]GTPgammaS binding in rat hippocampal tissue, vilazodone was demonstrated to have an intrinsic activity comparable to the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Vilazodone (1-10 mg/kg p.o.) dose-dependently displaced in vivo [3H]DASB (N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine) binding from rat cortex and hippocampus, indicating that vilazodone occupies 5-HT transporters in vivo. Using in vivo microdialysis, vilazodone (10 mg/kg p.o.) was demonstrated to cause a 2-fold increase in extracellular 5-HT but no change in noradrenaline or dopamine levels in frontal cortex of freely moving rats"
Please do not be disturbed by detailed back up of my personal opinion, but since this is a new medication, medical literature excerpts should only help to educate those considering trying this medication. From the molecular structure of common SSRIs like paroxetine or fluoxetine, the chemical structure is definitely quite different, so I am hoping this has some hope. As far as "teleconference with marketers" - please, understand, they are paid to present their findings via utmost optimistic manner. If I was about to sell new antidepressant, during the teleconference with the marketers and shareholders, I would also sound very optimistic, pointing out how good this medication is.
Is the "best drug so far " or not, let's wait another week or two until someone tries it and posts their experience, and then maybe another year or two to see how they are holding up.
poster:bodhisattva_guy
thread:977653
URL: http://www.dr-bob.org/babble/20110130/msgs/978677.html